Alphatec Holdings, Inc. (NASDAQ:ATEC) Receives $17.50 Consensus PT from Analysts

Shares of Alphatec Holdings, Inc. (NASDAQ:ATEC - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the ten brokerages that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $17.50.

Several brokerages have weighed in on ATEC. Morgan Stanley downgraded Alphatec from an "overweight" rating to an "equal weight" rating in a research note on Thursday, August 1st. Barclays started coverage on shares of Alphatec in a report on Monday, July 8th. They issued an "overweight" rating and a $19.00 target price on the stock. Canaccord Genuity Group reaffirmed a "buy" rating and issued a $20.00 price objective on shares of Alphatec in a report on Friday, August 30th. Lake Street Capital cut their target price on Alphatec from $32.00 to $18.00 and set a "buy" rating for the company in a research note on Tuesday, September 3rd. Finally, HC Wainwright reissued a "buy" rating and issued a $20.00 price target on shares of Alphatec in a report on Thursday, August 1st.

Alphatec Stock Down 0.4 %

Shares of NASDAQ ATEC traded down $0.02 during midday trading on Tuesday, hitting $5.30. 1,702,422 shares of the company's stock were exchanged, compared to its average volume of 1,871,233. The firm's fifty day simple moving average is $5.90 and its 200-day simple moving average is $9.36. The company has a debt-to-equity ratio of 30.21, a current ratio of 2.22 and a quick ratio of 1.21. The company has a market cap of $741.39 million, a PE ratio of -3.56 and a beta of 1.39. Alphatec has a twelve month low of $4.88 and a twelve month high of $17.34.

Alphatec (NASDAQ:ATEC - Get Free Report) last released its quarterly earnings results on Wednesday, July 31st. The medical technology company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.26) by ($0.03). Alphatec had a negative return on equity of 816.57% and a negative net margin of 33.48%. The firm had revenue of $145.57 million for the quarter, compared to analysts' expectations of $144.55 million. During the same quarter in the prior year, the business earned ($0.43) EPS. The company's quarterly revenue was up 24.5% compared to the same quarter last year. Research analysts predict that Alphatec will post -1.08 EPS for the current fiscal year.

Insider Activity

In related news, Director David M. Demski acquired 50,000 shares of the business's stock in a transaction that occurred on Wednesday, August 21st. The stock was purchased at an average cost of $5.67 per share, for a total transaction of $283,500.00. Following the transaction, the director now directly owns 288,441 shares of the company's stock, valued at approximately $1,635,460.47. This trade represents a 0.00 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 22.80% of the company's stock.

Hedge Funds Weigh In On Alphatec

A number of institutional investors have recently made changes to their positions in the stock. Comerica Bank increased its position in Alphatec by 64.8% during the 1st quarter. Comerica Bank now owns 6,443 shares of the medical technology company's stock worth $89,000 after purchasing an additional 2,534 shares in the last quarter. Van ECK Associates Corp grew its holdings in shares of Alphatec by 11.8% during the second quarter. Van ECK Associates Corp now owns 12,275 shares of the medical technology company's stock worth $128,000 after buying an additional 1,300 shares in the last quarter. EntryPoint Capital LLC acquired a new position in shares of Alphatec in the first quarter valued at approximately $141,000. SG Americas Securities LLC lifted its stake in shares of Alphatec by 44.6% during the second quarter. SG Americas Securities LLC now owns 14,495 shares of the medical technology company's stock valued at $151,000 after buying an additional 4,472 shares during the period. Finally, Cetera Advisors LLC lifted its stake in shares of Alphatec by 15.6% during the first quarter. Cetera Advisors LLC now owns 12,720 shares of the medical technology company's stock valued at $175,000 after buying an additional 1,720 shares during the period. 66.35% of the stock is owned by institutional investors and hedge funds.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.